Valuation: Jasper Therapeutics, Inc.

Market Cap 23.96M 20.54M 19.24M 17.58M 33.17M 2.28B 33.5M 227M 88.36M 1.15B 89.98M 88.02M 3.82B P/E 2026 *
-1.08x
P/E 2027 * -0.65x
Enterprise Value -125M -107M -101M -91.85M -173M -11.94B -175M -1.19B -462M -6.02B -470M -460M -19.95B EV / Sales 2026 *
-52.2x
EV / Sales 2027 * -
Free-Float
97.44%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Jasper Therapeutics, Inc.

1 day-0.30%
1 week-3.97%
Current month+14.32%
1 month+4.62%
3 months-20.24%
6 months-48.56%
Current year-60.64%
1 week 0.67
Extreme 0.6735
0.76
1 month 0.55
Extreme 0.5502
0.97
Current year 0.32
Extreme 0.3151
2.07
1 year 0.32
Extreme 0.3151
2.98
3 years 0.32
Extreme 0.3151
31.01
5 years 0.32
Extreme 0.3151
188.8
10 years 0.32
Extreme 0.3151
188.8
Manager TitleAgeSince
Chief Executive Officer 54 05/01/2026
Director of Finance/CFO 54 21/09/2023
Chief Operating Officer 59 15/07/2026
Director TitleAgeSince
Director/Board Member 54 05/01/2026
Director/Board Member 70 03/09/2021
Director/Board Member 58 23/09/2021
Date Insider Type Main position Quantity % Market Cap.
31/07/26 Free

Founder

7,500 0.0267%
31/07/26 Free

Director

7,500 0.0267%
31/07/26 Free

Chairman

7,500 0.0267%
Change 5-day change 1-year change 3-year change Capi.($)
-0.30%-3.97%-75.67%-94.50% 23.96M
+3.31%-3.70%+61.03%+103.64% 71.35B
+1.74%+1.06%+49.02%+87.38% 64.17B
+1.09%+22.96%+8.55%-3.03% 28.65B
-0.07%-3.56%-3.45%+467.26% 27.06B
-1.34%+7.52%+57.88%+13.81% 27.33B
+3.98%+4.37%+39.47%-14.65% 20.47B
+1.02%+6.43%+269.42%+420.34% 19.36B
+0.29%+0.29%+8.11%+544.17% 15.96B
+3.98%+6.78%+49.66%+157.94% 14.05B
Average +1.37%+3.39%+46.40%+168.24% 28.84B
Weighted average by Cap. +1.74%+3.05%+55.76%+154.90%

Financials

2026 *2027 *
Net sales 2.4M 2.06M 1.93M 1.76M 3.32M 229M 3.35M 22.73M 8.85M 115M 9.01M 8.82M 382M -
Net income -19.7M -16.88M -15.82M -14.45M -27.27M -1.88B -27.54M -187M -72.63M -948M -73.97M -72.36M -3.14B -57.36M -49.15M -46.06M -42.07M -79.4M -5.47B -80.18M -543M -211M -2.76B -215M -211M -9.14B
Net Debt -149M -128M -120M -109M -207M -14.22B -209M -1.41B -550M -7.18B -560M -548M -23.77B -310M -266M -249M -227M -429M -29.56B -433M -2.94B -1.14B -14.91B -1.16B -1.14B -49.39B
Logo Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell-driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU), and Asthma. Its lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the c-Kit receptor, inhibiting signaling for mast cells and a maintenance signal for hematopoietic stem cells. KIT inhibition with briquilimab has demonstrated clinical outcomes both as a conditioning agent for stem cell transplant in SCID and Fanconi anemia. Its pipeline also includes KP-104 (vensobafusp alfa), a bifunctional complement inhibitor in clinical development, and KP-701, a preclinical B-cell receptor-targeted therapy.
Employees
22
Date Price Change Volume
25/08/26 US$0.7202 -0.30% 271,830
24/08/26 US$0.7224 +0.89% 354,236
21/08/26 US$0.7160 +3.59% 780,849
20/08/26 US$0.6912 -7.42% 2,336,050
19/08/26 US$0.7466 -0.45% 294,283
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
0.7202USD
Average target price
7.375USD
Spread / Average Target
+924.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JSPR Stock